Streetbeat News

Stock Prices

BPTH

Bio-Path Holdings presented interim results from its Phase 2 study of prexigebersen in combination with decitabine and venetoclax for treating acute myeloid leukemia at the 2024 European Hematology Association Congress. The data showed that prexigebersen is well-tolerated and has demonstrated compelling efficacy in both newly diagnosed and refractory/relapsed AML patients.

Portfolio Pulse from Benzinga Newsdesk

June 14, 2024 | 11:11 am

IIPR

Innovative Industrial Properties, Inc. (NYSE:IIPR) announced a 4.4% increase in its second quarter 2024 dividend to $1.90 per share, payable on July 15, 2024.

Portfolio Pulse from Benzinga Newsdesk

June 14, 2024 | 11:10 am

SNDX

Syndax Pharmaceuticals has disclosed updated data from multiple combination trials of revumenib, a potent small molecule Menin inhibitor, in patients with acute leukemias. The data shows promising results, with a 96% CRc observed in the BEAT AML trial and a 52% CRc in the AUGMENT-102 trial.

Portfolio Pulse from Benzinga Newsdesk

June 14, 2024 | 11:09 am

ENGN

enGene reported a Q2 EPS loss of $0.38, with a net loss of $15.0 million for the quarter ending April 30, 2024. The company exited the quarter with $264.8 million in cash and equivalents. The increased net loss is mainly due to higher operating expenses, partially offset by net interest income.

Portfolio Pulse from Benzinga Newsdesk

June 14, 2024 | 11:06 am

AAPL

IFRA

NVDA

Renowned investor Steve Eisman dismisses fears of a U.S. recession, citing strong market performance driven by AI and infrastructure investments. Eisman highlights the record highs of NVIDIA, Apple, and the iShares U.S. Infrastructure ETF as evidence of economic resilience.

Portfolio Pulse from Benzinga Neuro

June 14, 2024 | 11:03 am

BRK.A

BYDDF

Chinese automakers, led by Warren Buffett-backed BYD, have outsold U.S. brands for the first time, selling 13.4 million vehicles compared to 11.9 million by American brands. This growth is driven by competitive pricing and expansion into emerging markets, despite rising trade tensions and increased tariffs on Chinese EVs.

Portfolio Pulse from Benzinga Neuro

June 14, 2024 | 11:01 am

GLD

SPY

UNG

UUP

On June 13th, U.S. stock markets closed mixed with the Nasdaq and S&P 500 reaching record highs. Economic data showed a drop in U.S. producer prices and a rise in jobless claims. The Federal Reserve held interest rates steady. Most S&P 500 sectors fell, while tech and real estate stocks rose. Asian markets were mixed, with Japan's Nikkei 225 gaining and Australia's S&P/ASX 200 declining. European markets continued to decline, and commodities showed mixed performance. The U.S. Dollar Index advanced.

Portfolio Pulse from Akanksha Bakshi

June 14, 2024 | 11:00 am

OPT

Trading halt status updated at 7:00:00 AM ET with news and resumption times provided.

Portfolio Pulse from Benzinga Newsdesk

June 14, 2024 | 11:00 am

PNM

PNM Resources announced that its unit, Texas-New Mexico Power Company (TNMP), received approval for a $15.7 million annual increase in distribution investment recovery, effective July 28, 2024. This approval allows TNMP to recover over $205 million in net distribution infrastructure investments. Recent legislation permits semi-annual filings, reducing regulatory lag and supporting TNMP's investment plan for reliable growth.

Portfolio Pulse from Benzinga Newsdesk

June 14, 2024 | 10:40 am

STTK

Shattuck Labs disclosed updated interim data from its Phase 1B clinical trial of SL-172154 in combination with Azacitidine for higher-risk myelodysplastic syndromes (HR-MDS) and TP53 mutant acute myeloid leukemia (AML) patients. The trial showed a 67% Objective Response Rate (ORR) in HR-MDS patients and a 43% ORR in TP53m AML patients.

Portfolio Pulse from Benzinga Newsdesk

June 14, 2024 | 10:16 am